ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 29 of 57
УЖМБС 2020, 5(1): 199–203
Clinical Medicine

Comparative Evaluation of the Prokinetics Efficiency in the Treatment of Patients with Chronic Gastritis and Diabetes Mellitus 2 Type

Sirchak Y. S., Patskun S. V.

In diabetes mellitus, which accounts for about one–third of gastroparesis cases, unpredictable carbohydrate uptake can lead to increased glycemic variability and a tendency to hypoglycemia. Exposure to gastric or extra–gastric pathogenic factors may mediate the gastroparesis symptoms' severity. The symptoms associated with gastroparesis in patients with diabetes did not correlate with glycosylated hemoglobin levels or gastroparesis severity. The relevance of this topic is the approach to the treatment of patients with diabetes mellitus type 2 and chronic gastritis requires individualization, which requires not only the detection of Helicobacter pylori and antihelicobacter therapy but also the correction of the evacuation function of the stomach. The purpose of the study was to compare the efficacy between usage of itopride hydrochloride and domperidone in patients with diabetes mellitus 2 type and chronic gastritis. Material and methods. We examined 66 Helicobacter pylori positive patients with a combination of chronic gastritis and diabetes mellitus 2 type, who were treated in the endocrinology department of the Transcarpathia Regional Clinical Hospital named after A. Novak. The patients` mean age was 56.8±2.6 years. There were 39 (59.1%) women and 27 (40.9%) men among these patients. All patients were divided into two groups. The 1st group in addition to standard antihelicobacter pylori therapy received prokinetic itopride hydrochloride while the 2nd group received domperidone. Results and discussion. The better results of the clinical manifestations dynamics in the gastrointestinal tract were obtained in the 2nd group patients with diabetes mellitus 2 type and chronic gastritis associated with the Helicobacter pylori, who were treated with the drug domperidone compared with the 1st group where patients were treated with the drug itopride hydrochloride. Higher domperidone efficacy may be associated with slower gastric emptying under its influence. Conclusion. In patients with diabetes mellitus 2 type, the gastrointestinal lesions are quite common and are manifested by the following clinical symptoms: acid belching – 40.9 %, heartburn – 28.8 %, nausea – 57.6 %, feeling of difficulty in the epigastrium – 59 %, epigastric pain – 36.4 %. When treating patients with prokinetic domperidone, we observed an improvement in their condition, namely, the number of patients' complaints regarding acid belching, heartburn, nausea, feeling of difficulty in the epigastrium, and epigastric pain decreased.

Keywords: diabetes mellitus 2 type, chronic gastritis, prokinetics

Full text: PDF (Ukr) 212K

  1. Phillips LK, Deane AM, Jones KL, Rayner CK, Horowitz M. Gastric emptying and glycaemia in health and diabetes mellitus. Nature Reviews Endocrinology. 2015; 11.2: 112. PMID: 25421372.
  2. Farmer AD, Bruckner-Holt C, Schwartz S, Sadler E, Kadirkamanthan S. Diabetic gastroparesis: perspectives from a patient and health care providers. Journal of patient-centered research and reviews. 2019; 6(2): 148. PMID: 31414026. PMCID: PMC6676757.
  3. Lee AA, Hasler WL. Diabetes and the Stomach. Current treatment options in gastroenterology. 2017; 15(4): 441-59. PMID: 28879488.
  4. Marathe CS, Rayner CK, Jones KL, Horowitz M. Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care. 2013; 36:1396-405. PMID: 23613599. PMCID: PMC3631884.
  5. He X-D, Guo Y-M, Goyal RK. Еffect of hyperglycemia on Purinergic and nitrergic inhibitory neuromuscular Transmission in the antrum of the stomach: implications for Fast gastric emptying. Frontiers in medicine. 2018; 5: 1. PMID: 29410956. PMCID: PMC5787141.
  6. Koch KL, Hasler WL, Yates KP, Parkman HP, Pasricha PJ, Calles-Escandon J, et al. Baseline features and differences in 48-week clinical outcomes in patients with gastroparesis and type 1 vs type 2 diabetes. Neurogastroenterology & Motility. 2016; 28(7): 1001-15. PMID: 26946489. PMCID: PMC5319426.
  7. Fujishiro M, Kushiyama A, Yamazaki H, Kaneko S, Koketsu Y, Yamamotoya T, et al. Gastrointestinal symptom prevalence depends on disease duration and gastrointestinal region in type 2 diabetes mellitus. World journal of gastroenterology. 2017; 23(36): 6694. PMID: 29085214. PMCID: PMC5643290.
  8. Kandadai SK, Boswell MV. Antacids, Gastrointestinal Prokinetics, and Proton Pump Inhibitors. Essentials of Pharmacology for Anesthesia, Pain Medicine, and Critical Care. NY: Springer; 2015. p. 345-63.
  9. Acosta A, Camilleri M. Prokinetics in gastroparesis. Gastroenterology Clinics. 2015; 44(1): 97-111. PMID: 25667026.
  10. Reddymasu S, Soykan I, McCallum R. Domperidone: Review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol. 2007; 102: 1-10. PMID: 17488253.
  11. Heckert J, Parkman HP. Therapeutic response to domperidone in gastroparesis: A prospective study using the GCSI‐daily diary. Neurogastroenterology & Motility. 2018; 30(1): e13246. PMID: 29110425.
  12. Schey R, Saadi M, Midani D, Roberts AC, Parupalli R, Parkman HP. Domperidone to treat symptoms of gastroparesis: benefits and side effects from a large single-center cohort. Digestive diseases and sciences. 2016; 61(12): 3545-51. PMID: 27530760.